HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exiting Generics

Executive Summary

Just a couple of years ago, generics were all the rage in pharmaceutical development programs. Big pharma companies scrambled for ways to create generics franchises that would enable them to offer a broad array of products to managed care customers. But now, with HMR's sale of its Rugby-Darby Group to Watson Pharmaceuticals, we seem to be in the midst of a major bail out. It's now clear that the smartest generics strategy is a no-generics strategy.

You may also be interested in...



Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.

Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry

In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.

TytoCare Raised $50m In Funding Amid Rising Demand To Remotely Monitor COVID-19 Patients

TytoCare has raised $50m in funding, which will be used to expand the reach of its telehealth solutions.

Topics

Related Companies

UsernamePublicRestriction

Register

IV000751

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel